胆固醇与冠心病的百年历程：从斑块到基因再到他汀类药物
A century of cholesterol and coronaries: from plaques to genes to statins.
作者信息
Goldstein Joseph L, Brown Michael S
机构信息
Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
出版信息
Cell. 2015 Mar 26;161(1):161-172. doi: 10.1016/j.cell.2015.01.036.
Abstract
One-fourth of all deaths in industrialized countries result from coronary heart disease. A century of research has revealed the essential causative agent: cholesterol-carrying low-density lipoprotein (LDL). LDL is controlled by specific receptors (LDLRs) in liver that remove it from blood. Mutations that eliminate LDLRs raise LDL and cause heart attacks in childhood, whereas mutations that raise LDLRs reduce LDL and diminish heart attacks. If we are to eliminate coronary disease, lowering LDL should be the primary goal. Effective means to achieve this goal are currently available. The key questions are: who to treat, when to treat, and how long to treat.
摘要
在工业化国家，四分之一的死亡是由冠心病导致的。一个世纪的研究已揭示出其主要致病因素：携带胆固醇的低密度脂蛋白（LDL）。LDL由肝脏中的特定受体（LDLR）控制，这些受体可将其从血液中清除。消除LDLR的突变会使LDL升高，并在儿童期引发心脏病发作，而增加LDLR的突变则会降低LDL并减少心脏病发作。如果我们要消除冠心病，降低LDL应是首要目标。目前已有实现这一目标的有效方法。关键问题是：治疗谁、何时治疗以及治疗多久。
相似文献
1
A century of cholesterol and coronaries: from plaques to genes to statins.胆固醇与冠心病的百年历程：从斑块到基因再到他汀类药物
Cell. 2015 Mar 26;161(1):161-172. doi: 10.1016/j.cell.2015.01.036.
2
Atherosclerosis: Making a U Turn.动脉粥样硬化：U 型转弯。
Annu Rev Med. 2020 Jan 27;71:191-201. doi: 10.1146/annurev-med-042418-011108.
3
Hypercholesterolemia: The role of PCSK9.高胆固醇血症：前蛋白转化酶枯草溶菌素9的作用
Arch Biochem Biophys. 2017 Jul 1;625-626:39-53. doi: 10.1016/j.abb.2017.06.001. Epub 2017 Jun 3.
4
Statins and the coronary plaque calcium "paradox": Insights from non-invasive and invasive imaging.他汀类药物与冠状动脉斑块钙化“悖论”：来自无创和有创成像的见解
Atherosclerosis. 2015 Aug;241(2):783-5. doi: 10.1016/j.atherosclerosis.2015.05.021. Epub 2015 Jun 3.
5
Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.瑞舒伐他汀独立于降低血浆胆固醇水平减少载脂蛋白 E/清道夫受体 B1 双重基因敲除小鼠主动脉窦和冠状动脉粥样硬化
Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):26-39. doi: 10.1161/ATVBAHA.117.305140. Epub 2017 Nov 21.
6
The impact of statins treatments for plaque characteristics in stable angina pectoris patients with very low and high low-density lipoprotein cholesterol levels: an intracoronary optical coherence tomography study.他汀类药物治疗极低和高 LDL 胆固醇水平稳定型心绞痛患者斑块特征的影响：一项冠状动脉光学相干断层成像研究。
Heart Vessels. 2024 Jun;39(6):475-485. doi: 10.1007/s00380-024-02359-9. Epub 2024 Feb 21.
7
Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease.在接受他汀类药物治疗的冠心病患者中，较低水平的低密度脂蛋白胆固醇与薄帽纤维粥样斑块的患病率较低相关。
J Clin Lipidol. 2022 Jan-Feb;16(1):104-111. doi: 10.1016/j.jacl.2021.11.012. Epub 2021 Dec 4.
8
Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels.冠状动脉疾病患者中实现极低低密度脂蛋白胆固醇水平时的斑块微观结构。
Atherosclerosis. 2015 Oct;242(2):490-5. doi: 10.1016/j.atherosclerosis.2015.08.005. Epub 2015 Aug 8.
9
Pitavastatin: an overview.匹伐他汀：概述
Atheroscler Suppl. 2011 Nov;12(3):271-6. doi: 10.1016/S1567-5688(11)70886-8.
10
Pleiotropic Effects of Statins on the Cardiovascular System.他汀类药物对心血管系统的多效性作用
Circ Res. 2017 Jan 6;120(1):229-243. doi: 10.1161/CIRCRESAHA.116.308537.
引用本文的文献
1
A comprehensive analysis identifies and validates NPC1 as a potential biomarker for prognosis in HCC.一项全面分析确定并验证了NPC1作为肝癌预后潜在生物标志物的地位。
Front Genet. 2025 Aug 13;16:1588583. doi: 10.3389/fgene.2025.1588583. eCollection 2025.
2
MBTPS1: a membrane-bound transcription factor protease implicated in the pathogenesis of several skin and skeletal disorders.MBTPS1：一种与多种皮肤和骨骼疾病发病机制相关的膜结合转录因子蛋白酶。
Funct Integr Genomics. 2025 Aug 29;25(1):178. doi: 10.1007/s10142-025-01694-y.
3
Effects of Novel Nutraceutical Combination on Lipid Pattern of Subjects with Sub-Optimal Blood Cholesterol Levels.新型营养保健品组合对血液胆固醇水平未达最佳状态受试者血脂模式的影响。
Biomedicines. 2025 Aug 9;13(8):1948. doi: 10.3390/biomedicines13081948.
4
Machine Learning for Predicting Thromboembolic Events Following Flow Diverter Treatment of Intracranial Aneurysms: A Multicenter Retrospective Study.机器学习用于预测颅内动脉瘤血流导向治疗后的血栓栓塞事件：一项多中心回顾性研究
Neurol Ther. 2025 Aug 27. doi: 10.1007/s40120-025-00808-9.
5
The causal effects of remnant cholesterol on increased risk of cardiovascular diseases in East Asians.残余胆固醇对东亚人心血管疾病风险增加的因果效应。
BMC Med. 2025 Aug 26;23(1):495. doi: 10.1186/s12916-025-04329-y.
6
Cholesterol homeostasis and pathway enrichment in post-revascularization recovery.血管再通后恢复过程中的胆固醇稳态与通路富集
Biomed Eng Online. 2025 Aug 9;24(1):98. doi: 10.1186/s12938-025-01429-x.
7
Depot-Specific Roles for C/EBPα in White Adipose Tissue Development and Metabolism.C/EBPα在白色脂肪组织发育和代谢中的特定储存库作用。
bioRxiv. 2025 Jul 26:2025.07.22.666007. doi: 10.1101/2025.07.22.666007.
8
Insights into Binding Mechanisms of Potential Inhibitors Targeting PCSK9 Protein via Molecular Dynamics Simulation and Free Energy Calculation.通过分子动力学模拟和自由能计算洞察靶向前蛋白转化酶枯草溶菌素9（PCSK9）蛋白的潜在抑制剂的结合机制
Molecules. 2025 Jul 14;30(14):2962. doi: 10.3390/molecules30142962.
9
Cerebral Small Vessel Disease: Therapeutic Approaches Targeting Neuroinflammation, Oxidative Stress, and Endothelial Dysfunction.脑小血管病：针对神经炎症、氧化应激和内皮功能障碍的治疗方法
Curr Issues Mol Biol. 2025 Mar 27;47(4):232. doi: 10.3390/cimb47040232.
10
Assessment of lipid parameters and its association with risk of stage 1 hypertension: a cohort study in middle-aged and elderly Chinese.血脂参数评估及其与1级高血压风险的关联：一项针对中国中老年人群的队列研究
Aging (Albany NY). 2025 Jul 14;17(7):1868-1880. doi: 10.18632/aging.206280.
本文引用的文献
1
Inactivating mutations in NPC1L1 and protection from coronary heart disease.NPC1L1基因的失活突变与冠心病防护
N Engl J Med. 2014 Nov 27;371(22):2072-82. doi: 10.1056/NEJMoa1405386. Epub 2014 Nov 12.
2
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.亲历前蛋白转化酶枯草溶菌素9的探索历程：从家族性高胆固醇血症中一种新基因的发现到一类潜在新型抗胆固醇药物的诞生
Curr Atheroscler Rep. 2014 Sep;16(9):439. doi: 10.1007/s11883-014-0439-8.
3
Deaths: leading causes for 2010.死亡：2010年的主要死因。
Natl Vital Stat Rep. 2013 Dec 20;62(6):1-96.
4
Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.PCSK9 单克隆抗体 AMG 145 对家族性高胆固醇血症纯合子患者的疗效。
Circulation. 2013 Nov 5;128(19):2113-20. doi: 10.1161/CIRCULATIONAHA.113.004678. Epub 2013 Sep 6.
5
Mechanisms and cellular functions of intramembrane proteases.膜内蛋白酶的作用机制及细胞功能
Biochim Biophys Acta. 2013 Dec;1828(12):2797-800. doi: 10.1016/j.bbamem.2013.07.001. Epub 2013 Jul 4.
6
Combating the epidemic of heart disease.抗击心脏病疫情
JAMA. 2012 Dec 26;308(24):2624-5. doi: 10.1001/jama.2012.164971.
7
Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的作用：载脂蛋白 B 代谢物单克隆抗体 AMG 145 降低杂合子家族性高胆固醇血症患者低密度脂蛋白胆固醇的随机试验（RUTHERFORD）
Circulation. 2012 Nov 13;126(20):2408-17. doi: 10.1161/CIRCULATIONAHA.112.144055. Epub 2012 Nov 5.
8
Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.低密度脂蛋白受体基因家族性高胆固醇血症变异数据库：更新与病理评估
Ann Hum Genet. 2012 Sep;76(5):387-401. doi: 10.1111/j.1469-1809.2012.00724.x.
9
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.他汀类药物降低 LDL 胆固醇对低血管疾病风险人群的影响：27 项随机试验个体数据的荟萃分析。
Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17.
10
PCSK9 inhibition: the next statin?前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：下一种他汀类药物？
J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31.
Zotero 插件